ZA200410229B - Administration of therapeutic viruses - Google Patents

Administration of therapeutic viruses

Info

Publication number
ZA200410229B
ZA200410229B ZA200410229A ZA200410229A ZA200410229B ZA 200410229 B ZA200410229 B ZA 200410229B ZA 200410229 A ZA200410229 A ZA 200410229A ZA 200410229 A ZA200410229 A ZA 200410229A ZA 200410229 B ZA200410229 B ZA 200410229B
Authority
ZA
South Africa
Prior art keywords
administration
therapeutic viruses
viruses
therapeutic
Prior art date
Application number
ZA200410229A
Other languages
English (en)
Inventor
Robert M Lorence
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of ZA200410229B publication Critical patent/ZA200410229B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200410229A 2002-06-21 2004-12-20 Administration of therapeutic viruses ZA200410229B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39063202P 2002-06-21 2002-06-21

Publications (1)

Publication Number Publication Date
ZA200410229B true ZA200410229B (en) 2006-07-26

Family

ID=30000590

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200410229A ZA200410229B (en) 2002-06-21 2004-12-20 Administration of therapeutic viruses

Country Status (11)

Country Link
US (2) US20050220818A1 (fr)
EP (2) EP2266601A1 (fr)
JP (1) JP2006511450A (fr)
AU (1) AU2003243307B2 (fr)
CA (1) CA2489523A1 (fr)
IL (1) IL165860A0 (fr)
MX (1) MXPA04012881A (fr)
NZ (1) NZ537255A (fr)
RU (1) RU2314830C2 (fr)
WO (1) WO2004000209A2 (fr)
ZA (1) ZA200410229B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005244768B2 (en) 2004-04-27 2011-06-09 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ATE540698T1 (de) 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
EP2327764B1 (fr) 2009-11-30 2011-12-28 United Cancer Research Institute Nouveau clone du virus de la maladie de Newcastle, sa fabrication et son application dans le traitement médical du cancer
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (fr) 2012-04-20 2013-10-24 Genelux Corporation Méthodes d'imagerie pour virothérapie oncolytique
WO2014055960A1 (fr) 2012-10-05 2014-04-10 Genelux Corporation Procédés diagnostiques et thérapeutiques basés sur l'absorption d'énergie utilisant des molécules d'acide nucléique codant pour des enzymes productrices de chromophore
WO2015103438A2 (fr) 2014-01-02 2015-07-09 Genelux Corporation Traitement d'appoint par un virus oncolytique avec des agents qui augmentent l'infectivité du virus
CA3203273A1 (fr) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions d'adenosine deaminase-2, variants et methodes d'utilisation
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
NZ746934A (en) 2016-04-15 2023-11-24 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd155 et leurs utilisations
CN110352245A (zh) 2016-10-20 2019-10-18 高山免疫科学股份有限公司 可分泌变体免疫调节蛋白和工程化细胞疗法
CA3052473A1 (fr) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Cellules tueuses naturelles (nk) modifiees et compositions et procedes associes
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
RS64870B1 (sr) 2017-03-16 2023-12-29 Alpine Immune Sciences Inc Imunomodulatorni proteini varijante pd-l1 i njihove upotrebe
TW201925223A (zh) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
AU2019282239B2 (en) 2018-06-04 2024-06-06 Calidi Biotherapeutics (Nevada), Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (fr) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Protéines immunomodulatrices de variants de pd-l1 et utilisations associées
EP3844276A2 (fr) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Souches bactériennes immunostimulatrices modifiées et utilisations associées
CN113271955A (zh) 2018-11-06 2021-08-17 卡利迪生物治疗有限公司 用于细胞介导的溶瘤病毒疗法的增强的系统
EP3884041A2 (fr) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Procédés d'amplification d'un sous-ensemble de cellules tueuses naturelles (nk) et compositions et procédés associés
WO2020113141A2 (fr) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants cd86 et leurs utilisations
SG11202108459QA (en) 2019-02-27 2021-09-29 Actym Therapeutics Inc Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20230190801A1 (en) 2020-04-22 2023-06-22 Indapta Therapeutics, Inc. Natural killer (nk) cell compositions and methods for generating same
WO2021258008A1 (fr) * 2020-06-19 2021-12-23 Immunacor Llc Compositions et méthodes de traitement et de prévention d'infection virale
WO2022147480A1 (fr) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Virus oncolytique codant pour la sialidase et agent de ciblage de cellule immunitaire multispécifique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
EP1486211B1 (fr) * 1993-04-30 2008-10-22 Wellstat Biologics Corporation Compositions pour le traitement du cancer à l'aide de virus
EP0848956A1 (fr) * 1996-12-17 1998-06-24 Dimminaco Ag/Sa/Ltd. In ovo vaccination contre la maladie de Newcastle
US7470426B1 (en) * 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
ATE371372T1 (de) * 1997-10-09 2007-09-15 Wellstat Biologics Corp Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
AU4246900A (en) * 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
US20050074901A1 (en) * 2002-02-13 2005-04-07 John Castracane Methods and assays for detecting and quantifying the human p53 inducible gene protein
US20040131595A1 (en) * 2002-11-05 2004-07-08 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeutic viruses

Also Published As

Publication number Publication date
US20050220818A1 (en) 2005-10-06
JP2006511450A (ja) 2006-04-06
WO2004000209A3 (fr) 2005-03-03
MXPA04012881A (es) 2005-07-05
RU2314830C2 (ru) 2008-01-20
EP1539230A2 (fr) 2005-06-15
CA2489523A1 (fr) 2003-12-31
US20090180993A1 (en) 2009-07-16
AU2003243307A1 (en) 2004-01-06
EP1539230A4 (fr) 2007-10-31
WO2004000209A2 (fr) 2003-12-31
IL165860A0 (en) 2006-01-15
EP2266601A1 (fr) 2010-12-29
RU2005101351A (ru) 2005-08-10
NZ537255A (en) 2009-04-30
AU2003243307B2 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
ZA200410229B (en) Administration of therapeutic viruses
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
HK1073997A1 (en) Administration of agents for the treatment of inflammation
AU2003224725A8 (en) Hiv therapeutic
IL172733A0 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
HK1095036A1 (en) Virus therapeutic drug
EP1487411A4 (fr) Formulations therapeutiques soutenues respirables
HK1078784A1 (en) Therapeutic treatment
IL166337A0 (en) Oral administration of calctionin
AU2003279911A8 (en) Therapeutic formulations
TWI319400B (en) Piperazinylacylpiperidine derivatives, their preparation and their therapeutic application
AU2003294318A8 (en) Therapeutic bioconjugates
GB0223367D0 (en) Therapeutic treatment
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
GB0202900D0 (en) Novel formulations of drugs
HK1074444A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
EP1670755A4 (fr) Analogues de pyrovalerone et utilisations therapeutiques
GB0210464D0 (en) Therapeutic treatment
IL165612A0 (en) Novel arylimidazole derivatives preparation and therapeutic uses thereof
GB0210741D0 (en) Methods of therapy
AU2003296385A8 (en) Therapeutic single dose gas administration system
EP1485077A4 (fr) Therapie par association de medicaments